Ocular Surface Disease

This year was brimming with advancements in eye care.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

Inside the role of blepharitis in ocular surface disease and effective management strategies.

All 6 biomarkers in the study demonstrated improvement with the treatment of lifitegrast, according to Thimons.

The retrospective study investigated and analyzed the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

What we know and what we do not know…yet.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, tackled new and exciting ways to tackle meibomian gland dysfunction alongside fellow ocular surface specialist Rana Taji, OD, MSc, FAAO, at AAOpt 2024.

The lipid-containing lubricating drop established noninferiority in comfort when compared to non-lipid drops, and the lipid-containing group also exhibited statistically significant improvements in visual quality at both day 7 and day 30, highlighting the potential benefits of this formulation for patients.

At the Tear Film and Ocular Surface meeting in Venice, Dr. Melissa Toyos shares findings on the mechanism of action of brimonidine tartrate.

New research sheds light on how the dry eye medication lifitegrast works beyond the ocular surface, targeting the underlying immune system to provide relief for patients.

There’s more to dry eye treatment than eye drops.

Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.

Choosing the best lens is a puzzle that requires consideration of all the pieces.

Ben Casella, OD, FAAO, chief optometric editor for Optometry Times®, gives a preview of what to expect at this year's EyeCon.

Pamela E. Theriot, OD, FAAO, chats about the relationship between makeup and the ocular surface, and when and how how to intervene as a medical professional.

Actionable tips to improve comfort and fit.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

Long-term vision and ocular surface health are just part of the puzzle.

Pediatric TINU syndrome is rare, but responds well to treatment.

The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.

Tracy Lynn Schroeder Swartz, OD, MS, FAAO, overview the 3 questions to ask before referring a patient for refractive surgery.

Walter Whitley, OD, MBA, FAAO, weighs in on the importance of staying in the know of innovations in treatment options for the sake of patient care.

Gromacki shares the importance of a dedicated approach to treating keratoconus, highlighting the need for passion, diverse tools, and a committed practice environment to ensure patient success.

Exploring strategies for effective management of a multifaceted condition.

Jade Coats, OD, details 2 poster presentations on the benefits found in a novel lipid-containing eye drop during AOA's 2024 Optometry's Meeting.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

Honest discussions about treatments for dry eye disease can enhance compliance and simplify care.